MDxHealth Pivots Strategy Amid Medicare Headwinds, UTI Unit Shutdown
$MDXH reports Q1 revenue growth of 13% but discontinues UTI business and lab due to reimbursement challenges. Company narrows focus to prostate cancer diagnostics.
MDXHartificial intelligencerestructuring